Sionna Therapeutics, Inc. (SION)

NGM – Real Time Price. Currency in USD

6.08

+0.98 (19.25%)

Market open: Aug 12, 2026, 11:15 AM EDT

4.91

-0.19 (-3.74%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

11.08.2026

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.

10.08.2026

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ:SION) announced topline clinical trial results from two nucleotide binding domain 1 (NBD1) stabilizer candidate programs targeting cystic fibrosis (CF).

10.08.2026

Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Monday.

10.08.2026

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.

10.08.2026

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

10.08.2026

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

San Diego, California--(Newsfile Corp. - August 10, 2026) - Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). Click here to join the investigation.

10.08.2026

Sionna scraps genetic disorder drug program after trial setback; shares tank

Sionna Therapeutics said on Monday it would stop developing its experimental drug as an addition to standard treatment for a type of genetic ‌disorder after it failed to show a meaningful benefit in a mid-stage trial.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
SION	BTIG Research	Neutral	undefined >> undefined	August 10th 2026
SION	Guggenheim	Neutral	undefined >> undefined	August 10th 2026
SION	Citizens	Market Perform	undefined >> undefined	August 10th 2026
SION	Raymond James	Market Perform	undefined >> undefined	August 10th 2026
SION	RBC Capital Mkts	Sector Perform	undefined >> $5	August 10th 2026
SION	Wedbush	Neutral	undefined >> $5	August 10th 2026
SION	Stifel	Hold	undefined >> $7	August 10th 2026

Press releases

10.08.2026

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

06.08.2026

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

Sionna Therapeutics, Inc. (SION)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sionna Therapeutics, Inc. (SION)

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna scraps genetic disorder drug program after trial setback; shares tank

Videos

No Data

Upgrades / Downgrades

Press releases

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna scraps genetic disorder drug program after trial setback; shares tank

Videos

No Data

Upgrades / Downgrades

Press releases

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

Search stocks

Sionna Therapeutics, Inc. (SION)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sionna Therapeutics, Inc. (SION)

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna scraps genetic disorder drug program after trial setback; shares tank

Videos

No Data

Upgrades / Downgrades

Press releases

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna scraps genetic disorder drug program after trial setback; shares tank

Videos

No Data

Upgrades / Downgrades

Press releases

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

Sionna Therapeutics Reports Second Quarter 2026 Financial Results